Hutchmed registers Phase III trial of HMPL-306 in postoperative residual or recurrent grade 2 glioma
The study plans to enroll 210 participants and plans to begin in November 2026, with primary completion projected for March 2032. It is a randomized, double-blind, placebo-controlled multicenter Phase III trial evaluating HMPL-306 tablet safety and efficacy.
Primary source
ClinicalTrials.gov registry record, November 3, 2026
HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
Read the source: HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation